Atosiban

Atosiban is a peptide analogue of oxytocin but with oxytocin properties. It has been investigated by IV-inf as a tocolytic in the management of premature labor, but there is some concern about adverse effects on the fetus.

Brands

Adult Dose

Neonatal

Paedriatic

Characteristics

. It is of Synthetic origin. . The Molecular Weight of Atosiban is 994.20.

Contraindications

Atosiban is contraindicated in conditions like Placenta previa,Nausea and vomiting of terminal illness,Motor TICS and adjunctive treatment in chorea,Autoimmune conditions,Dermatological conditions caused or aggravated by sunlight,Eclampsia,Intrauterine fetal death,Antepartum haemorrhage.

Effects

The symptomatic adverse reactions produced by Atosiban are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Nausea, Vomiting, Fever, Tachycardia, Insomnia, Rashes, Hot flushes, Hyperglycemia, Injection site reactions.

Indications

Atosiban is primarily indicated in conditions like Prostate cancer, flare with initial gonadorelin therapy, Uncomplicated premature labor.

Interactions

No data regarding the interactions of Atosiban was found.

Interfrence

Risks

If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Storage

infusions Store in a well closed container, Below 15°C.

Warnings

Monitor blood loss after delivery;Intra-uterine growth retardation; hepatic impairment ,renal impairment

Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.